Cargando…
One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
The aim of this study was to investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration, and to explore the predictive factors for visual outcome. This is a prospective interventional case series. Fifty-two eyes of 52 treatment-naïve age-related...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081167/ https://www.ncbi.nlm.nih.gov/pubmed/30075585 http://dx.doi.org/10.1097/MD.0000000000011737 |
_version_ | 1783345616727834624 |
---|---|
author | Ono, Aoi Shiragami, Chieko Manabe, Saki Takasago, Yukari Osaka, Rie Kobayashi, Mamoru Yamashita, Ayana Tsujikawa, Akitaka Hirooka, Kazuyuki |
author_facet | Ono, Aoi Shiragami, Chieko Manabe, Saki Takasago, Yukari Osaka, Rie Kobayashi, Mamoru Yamashita, Ayana Tsujikawa, Akitaka Hirooka, Kazuyuki |
author_sort | Ono, Aoi |
collection | PubMed |
description | The aim of this study was to investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration, and to explore the predictive factors for visual outcome. This is a prospective interventional case series. Fifty-two eyes of 52 treatment-naïve age-related-macula-degeneration patients were enrolled. All participants received IVA bimonthly following 3 monthly loading dose. The primary endpoint was change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), and the secondary outcomes included changes in subfoveal choroidal thickness (SCT), macular atrophy (MA), and retinal average sensitivity (AS) determined by microperimetry at 12 months compared with baseline. The predictive factors for the change of BCVA were examined. Of 52 enrolled patients, 4 patients were drop out. Remaining 48 patients were examined. Mean logMAR BCVA significantly improved from 0.42 ± 0.37 at baseline to 0.29 ± 0.34 at 12 months (P = .008). Mean CRT and SCT significant reduced from 285.6 ± 135.2 μm, 247.9 ± 96.7 μm at baseline to 233.4 ± 98.0 μm, 208.1 ± 94.6 μm at 12 months, respectively (P < .001). At 12 months, 35 eyes of 48 eyes (72.3%) were archived dry macula. MA occurred in 7 eyes of 35 eyes with dry macula at 12 months (20.0%). AS was significant improved (P = .027) between baseline (median: 15.7 dB) and 12 months (median: 19.5 dB). The BCVA of the cases with MA involved fovea was significant worse. Age was significantly predicted for the BCVA at 12 months. IVA administered over 1 year improved BCVA, AS, and morphological findings, and the predictive factors for BCVA were age and MA-involved fovea. |
format | Online Article Text |
id | pubmed-6081167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-60811672018-08-17 One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis Ono, Aoi Shiragami, Chieko Manabe, Saki Takasago, Yukari Osaka, Rie Kobayashi, Mamoru Yamashita, Ayana Tsujikawa, Akitaka Hirooka, Kazuyuki Medicine (Baltimore) Research Article The aim of this study was to investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration, and to explore the predictive factors for visual outcome. This is a prospective interventional case series. Fifty-two eyes of 52 treatment-naïve age-related-macula-degeneration patients were enrolled. All participants received IVA bimonthly following 3 monthly loading dose. The primary endpoint was change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), and the secondary outcomes included changes in subfoveal choroidal thickness (SCT), macular atrophy (MA), and retinal average sensitivity (AS) determined by microperimetry at 12 months compared with baseline. The predictive factors for the change of BCVA were examined. Of 52 enrolled patients, 4 patients were drop out. Remaining 48 patients were examined. Mean logMAR BCVA significantly improved from 0.42 ± 0.37 at baseline to 0.29 ± 0.34 at 12 months (P = .008). Mean CRT and SCT significant reduced from 285.6 ± 135.2 μm, 247.9 ± 96.7 μm at baseline to 233.4 ± 98.0 μm, 208.1 ± 94.6 μm at 12 months, respectively (P < .001). At 12 months, 35 eyes of 48 eyes (72.3%) were archived dry macula. MA occurred in 7 eyes of 35 eyes with dry macula at 12 months (20.0%). AS was significant improved (P = .027) between baseline (median: 15.7 dB) and 12 months (median: 19.5 dB). The BCVA of the cases with MA involved fovea was significant worse. Age was significantly predicted for the BCVA at 12 months. IVA administered over 1 year improved BCVA, AS, and morphological findings, and the predictive factors for BCVA were age and MA-involved fovea. Wolters Kluwer Health 2018-08-03 /pmc/articles/PMC6081167/ /pubmed/30075585 http://dx.doi.org/10.1097/MD.0000000000011737 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Ono, Aoi Shiragami, Chieko Manabe, Saki Takasago, Yukari Osaka, Rie Kobayashi, Mamoru Yamashita, Ayana Tsujikawa, Akitaka Hirooka, Kazuyuki One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title | One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title_full | One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title_fullStr | One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title_full_unstemmed | One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title_short | One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
title_sort | one-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081167/ https://www.ncbi.nlm.nih.gov/pubmed/30075585 http://dx.doi.org/10.1097/MD.0000000000011737 |
work_keys_str_mv | AT onoaoi oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT shiragamichieko oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT manabesaki oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT takasagoyukari oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT osakarie oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT kobayashimamoru oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT yamashitaayana oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT tsujikawaakitaka oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis AT hirookakazuyuki oneyearoutcomesoffixedtreatmentofintravitrealafliberceptforexudativeagerelatedmaculardegenerationandthefactorofvisualprognosis |